ERBB2 and breast carcinoma: Furthermore, a phase III study reported in the 2012 American Society of Clinical Oncology Annual Meeting found that, metastatic HER2-positive breast cancer patients who received lapatinib and chemotherapy had shorter PFS than those receiving trastuzumab and chemotherapy [22].